Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

Vascular endothelial growth factor receptor 2 (VEGFR2) is an essential factor in tumor angiogenesis and in the growth of pancreatic cancer. Immunotherapy using epitope peptide for VEGFR2 (VEGFR2‐169) that we identified previously is expected to improve the clinical outcome. Therefore, a phase I clin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2010-02, Vol.101 (2), p.433-439
Hauptverfasser:	Miyazawa, Motoki, Ohsawa, Ryuji, Tsunoda, Takuya, Hirono, Seiko, Kawai, Manabu, Tani, Masaji, Nakamura, Yusuke, Yamaue, Hiroki
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Biological and medical sciences Cancer Vaccines - therapeutic use Combined Modality Therapy Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Gastroenterology. Liver. Pancreas. Abdomen Gemcitabine Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Original Pancreatic Neoplasms - immunology Pancreatic Neoplasms - mortality Pancreatic Neoplasms - therapy Peptide Fragments - immunology Peptide Fragments - therapeutic use T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Regulatory - immunology Tumors Vascular Endothelial Growth Factor Receptor-2 - immunology Vascular Endothelial Growth Factor Receptor-2 - therapeutic use
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!